What is the secukinumab loading dose and how is it given?
Secukinumab (Cosentyx) uses an initial higher-dose period (often called a “loading dose”) before moving to a maintenance schedule. In most prescribing schedules, the loading phase consists of dosing every 1 week at the start, then switching to less frequent dosing for maintenance. The exact loading and maintenance schedule depends on the indication and the starting dose strength your prescriber selected (typically 150 mg or 300 mg).
How do the loading dose schedules differ by indication?
Secukinumab loading-dose regimens can vary across approved uses such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. The key difference is usually the total initial dose selected (often 150 mg vs 300 mg) and the frequency during the induction period before maintenance begins.
If I miss a loading dose, what should I do?
Missing an induction/loading dose can shift when you transition to maintenance dosing. Guidance generally focuses on restarting the next scheduled dose rather than “catching up” with extra doses, but the correct approach depends on when the dose was missed and your indication. Your prescriber or pharmacist should confirm the plan based on your dosing history.
What injection schedule comes after the loading period?
After the initial weekly induction phase, secukinumab typically moves to maintenance dosing every 4 weeks (or other intervals depending on the indication and the selected dose). If you tell me your indication and whether you’re on 150 mg or 300 mg, I can help map the loading-to-maintenance transition more precisely.
Where can I verify the exact Cosentyx loading dose for my country/label?
Because dosing schedules can differ by label update and region, it helps to check the official product information for your locale. If you want, share your country and whether you’re using the 150 mg or 300 mg pens/syringes, and I’ll help you interpret the label wording you’re looking at.
Source
- DrugPatentWatch.com – secukinumab (Cosentyx) information